Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration.
- Author:
Ji Young LEE
1
;
Hyewon CHUNG
;
Hyung Chan KIM
Author Information
- Publication Type:Original Article
- Keywords: Anti-vascular endothelial growth factor; Choroidal neovascularization; Macular degeneration; Optical imaging; Spectral domain optical coherence tomography
- MeSH: Aged; Angiogenesis Inhibitors/*therapeutic use; Choroidal Neovascularization/classification/diagnostic imaging/*drug therapy; Female; Fluorescein Angiography; Fundus Oculi; Humans; Intravitreal Injections; Male; Middle Aged; Optical Imaging; Ranibizumab/*therapeutic use; Retrospective Studies; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A/*antagonists & inhibitors; Visual Acuity; Wet Macular Degeneration/classification/diagnostic imaging/*drug therapy
- From:Korean Journal of Ophthalmology 2016;30(1):17-24
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: To describe the changes of fundus autofluorescence (FAF) in patients with age-related macular degeneration before and after intravitreal injection of anti-vascular endothelial growth factor according to the type of choroidal neovascularization (CNV) and to evaluate the correlation of FAF with spectral domain optical coherence tomography (SD-OCT) parameters and vision. METHODS: This was a retrospective study. Twenty-one treatment-naive patients with neovascular age-related macular degeneration were included. Study eyes were divided into two groups according to the type of CNV. Fourteen eyes were type 1 CNV and seven eyes were type 2 CNV. All eyes underwent a complete ophthalmologic examination, including an assessment of best-corrected visual acuity, SD-OCT, fluorescein angiography, and FAF imaging, before and 3 months after intravitreal anti-vascular endothelial growth factor injection. Gray scales of FAF image for CNV areas, delineated as in fluorescein angiography, were analyzed using the ImageJ program, which were adjusted by comparison with normal background areas. Correlation of changes in FAF with changes in SD-OCT parameters, including CNV thickness, photoreceptor inner and outer segment junction disruption length, external limiting membrane disruption length, central macular thickness, subretinal fluid, and intraretinal fluid were analyzed. RESULTS: Eyes with both type 1 and type 2 CNV showed reduced FAF before treatment. The mean gray scales (%) of type 1 and type 2 CNV were 52.20% and 42.55%, respectively. The background values were 106.72 and 96.86. After treatment, the mean gray scales (%) of type 1 CNV and type 2 CNV were changed to 57.61% (p = 0.005) and 57.93% (p = 0.008), respectively. After treatment, CNV thickness, central macular thickness, and inner and outer segment junction disruption length were decreased while FAF increased. CONCLUSIONS: FAF was noted to be reduced in eyes with newly diagnosed wet age-related macular degeneration, but increased after anti-vascular endothelial growth factor therapy regardless of CNV lesion type.
